Table V.

Univariate and multivariate analysis of prognostic factors for recurrence-free survival.

	Univariate		Multivariate
Prognostic factor	HR (95%CI)	P-value	HR (95%CI)	P-value
MUC1 (≥0.056 vs. <0.056, ratio to GAPDH)	2.187 (1.171-4.083)	0.014	2.552 (1.294-5.032)	0.007
Bile duct invasion (yes vs. No)	2.445 (1.022-5.851)	0.045	3.979 (1.449-10.928)	0.007
Tumor diameter (>5 cm vs. ≤5 cm)	1.977 (1.026-3.810)	0.042	1.130 (0.509-2.510)	0.764
T stage (T2-4 vs. T1)	1.468 (1.039-2.073)	0.029	1.403 (0.931-2.115)	0.106
LN metastasis (yes vs. no)	2.449 (1.256-4.776)	0.009	2.053 (1.042-4.046)	0.038
Surrounding tissue invasion (yes vs. no)	2.045 (0.628-6.656)	0.235
CEA (≥20 ng/ml vs. <20 ng/ml)	1.108 (10.567-2.167)	0.764
CA-19-9 (≥37 ng/ml vs. <37 ng/ml)	0.828 (0.452-1.516)	0.540
Differentiation (poor vs. well)	1.930 (0.940-3.960	0.073
Tumor number (solitary vs. multiple)	1.504 (0.798-2.836)	0.207
Nerve invasion (yes vs. no)	2.217 (0.679-7.239)	0.187
Vascular invasion (yes vs. no)	0.971 (0.488-1.933)	0.933

LN, lymph node; HR, hazard ratio; CA, cancer antigen.